MD20150109A2 - Construcţii proteice mitocondriale şi utilizările acestora - Google Patents

Construcţii proteice mitocondriale şi utilizările acestora Download PDF

Info

Publication number
MD20150109A2
MD20150109A2 MDA20150109A MD20150109A MD20150109A2 MD 20150109 A2 MD20150109 A2 MD 20150109A2 MD A20150109 A MDA20150109 A MD A20150109A MD 20150109 A MD20150109 A MD 20150109A MD 20150109 A2 MD20150109 A2 MD 20150109A2
Authority
MD
Moldova
Prior art keywords
mitochondrial
mitochondrial proteins
disclosed
constructs
proteins constructs
Prior art date
Application number
MDA20150109A
Other languages
English (en)
Russian (ru)
Inventor
Хайя ЛОРБЕРБАУМ-ГАЛЬСКИЙ
Хагар Грейф
Original Assignee
Bio Blast Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd. filed Critical Bio Blast Pharma Ltd.
Publication of MD20150109A2 publication Critical patent/MD20150109A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)

Abstract

Invenţia se referă la medicină, în special la construcţii proteice mitocondriale şi utilizările acestora.Conform invenţiei, sunt dezvăluite construcţii proteice de fuziune noi ce includ o proteină mitocondrială funcţională. De asemenea, sunt dezvăluite metode de tratare a tulburărilor mitocondriale cu proteinele de fuziune dezvăluite şi compoziţiile acestora.
MDA20150109A 2013-04-15 2014-04-10 Construcţii proteice mitocondriale şi utilizările acestora MD20150109A2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361811934P 2013-04-15 2013-04-15
US201361869981P 2013-08-26 2013-08-26
US14/034,224 US8912147B2 (en) 2013-04-15 2013-09-23 Mitochondrial proteins constructs and uses thereof
PCT/IL2014/050354 WO2014170896A2 (en) 2013-04-15 2014-04-10 Mitochondrial proteins constructs and uses thereof

Publications (1)

Publication Number Publication Date
MD20150109A2 true MD20150109A2 (ro) 2016-03-31

Family

ID=51686951

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150109A MD20150109A2 (ro) 2013-04-15 2014-04-10 Construcţii proteice mitocondriale şi utilizările acestora

Country Status (13)

Country Link
US (1) US8912147B2 (ro)
EP (1) EP2986629B1 (ro)
JP (1) JP2016520557A (ro)
KR (1) KR20150143778A (ro)
AU (1) AU2014255313A1 (ro)
BR (1) BR112015026017A2 (ro)
CA (1) CA2909276A1 (ro)
EA (1) EA201501028A1 (ro)
MD (1) MD20150109A2 (ro)
MX (1) MX2015014424A (ro)
PE (1) PE20151774A1 (ro)
SG (1) SG11201508313TA (ro)
WO (1) WO2014170896A2 (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017178885A2 (en) 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
CA3122080A1 (en) * 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
JP2022520148A (ja) * 2018-12-06 2022-03-29 アークトゥラス・セラピューティクス・インコーポレイテッド 修飾タンパク質および関連の処置方法
CN110003345A (zh) * 2019-04-03 2019-07-12 天津师范大学 一种抗迟缓爱德华氏菌的TAT-EseD重组蛋白及用途
US20220378869A1 (en) 2019-07-18 2022-12-01 Larimar Therapeutics, Inc. Use of frataxin for treating leigh syndrome, french canadian type
US12566178B2 (en) 2019-07-29 2026-03-03 Larimar Therapeutics, Inc. Methods of quantifying frataxin and frataxin fusion proteins
DK4004022T3 (da) * 2019-07-29 2026-04-07 Univ Indiana Trustees Materialer og fremgangsmåder til behandling af friedreichs ataksi
US11988675B2 (en) 2019-11-25 2024-05-21 Larimar Therapeutics, Inc. Methods for quantifying frataxin activity
EP4114470A4 (en) 2020-03-03 2024-04-17 Arcturus Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY
WO2021195597A2 (en) * 2020-03-26 2021-09-30 Larimar Therapeutics, Inc. Molecules for organelle-specific protein delivery
BR112022021823A2 (pt) 2020-04-30 2023-01-17 Larimar Therapeutics Inc Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria
US12390509B2 (en) 2020-12-12 2025-08-19 Larimar Therapeutics, Inc. Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283444B2 (en) * 2003-10-24 2012-10-09 Wake Forest University Non-viral delivery of compounds to mitochondria
EP2300614B1 (en) 2008-02-04 2015-10-28 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods and compositions for treatment of mitochondrial disorders

Also Published As

Publication number Publication date
CA2909276A1 (en) 2014-10-23
AU2014255313A1 (en) 2015-09-10
KR20150143778A (ko) 2015-12-23
JP2016520557A (ja) 2016-07-14
US8912147B2 (en) 2014-12-16
WO2014170896A3 (en) 2014-12-31
BR112015026017A2 (pt) 2017-10-17
MX2015014424A (es) 2016-05-18
EA201501028A1 (ru) 2016-04-29
EP2986629B1 (en) 2017-11-08
EP2986629A2 (en) 2016-02-24
PE20151774A1 (es) 2015-12-20
US20140308262A1 (en) 2014-10-16
SG11201508313TA (en) 2015-11-27
WO2014170896A2 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX385845B (es) Usos y composiciones de la flagelina
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
NZ711445A (en) Fusion immunomodulatory proteins and methods for making same
HK1206638A1 (zh) 用於生产化妆品蛋白质和肽的修饰的多核苷酸
HUE038906T2 (hu) Kazein-makropeptidet tartalmazó magas protein-tartalmú denaturált tejsavó fehérje készítmények, ezeket tartalmazó termékek és ezek alkalmazása
MX2016007063A (es) Peptidos terapeuticos.
MX2016010953A (es) Proteinas de fc multimericas.
MA40475A (fr) Anticorps anti-tigit
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
EA201690314A1 (ru) Анти-garp-белок и его применения
MX384628B (es) Polipéptidos que tienen actividad de transgalactosilación.
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX375524B (es) Anticuerpos anti-axl.
PH12018500379B1 (en) Biopharmaceutical compositions
WO2015198240A3 (en) Compositions and methods for long acting proteins
MX2015016603A (es) Composiciones de corticosteroides.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)